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Objective: To reconstruct a sex-specific patient journey for Dutch persons with
Parkinson’s disease (PD) during the first 5 years after diagnosis.
Method: We analyzed a national administrative medical claims database containing data
of all patients newly diagnosed with PD between 2012 and 2016 in the Netherlands. We
performed time-to-event analysis to identify the moments when patients received care
from neurologists, allied healthcare therapists or general practitioners. We also extracted
relevant clinical milestones: unexpected hospitalization for PD, pneumonia, orthopedic
injuries, nursing home admission, and death. Using these data, we constructed the
patient journey stratified for sex.
Results: We included claims data of 13,518 men and 8,775 women with newly
diagnosed PD in the Netherlands. While we found little difference in neurologist
consultations, women visited general practitioners and physiotherapists significantly
earlier and more often (all p-values < 0.001). After 5 years, 37.9% (n = 3,326) of women
had visited an occupational therapist and 18.5% (n = 1,623) a speech and language
therapist at least once. This was 33.1% (n = 4,474) and 23.7% (n = 3,204) for men.
Approximately 2 years after diagnosis, PD-related complications (pneumonia, orthopedic
injuries, and PD-related hospitalization) occurred for the first time (women: 1.8 years;
men: 2.3 years), and after 5 years, 72.9% (n = 6,397) of women, and 68.7% (n = 9,287)
of men had experienced at least one.
Discussion: Considering the strengths and limitations of our methods, our findings
suggest that women experience complications and access most healthcare services
sooner after diagnosis and more frequently than men. The identified sex differences
extend the debate about phenotypical differences in PD between men and women.
Keywords: patient journey, Parkinson’s disease, sex difference, personalized care, healthcare usage, early
Parkinson’s disease
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INTRODUCTION
During the course of the disease, a patient with Parkinson’s
disease (PD) visits many different healthcare providers from
different disciplines (1). This “journey through the healthcare
system” varies per individual because of heterogeneity of
symptoms, differences in disease progression rate, and the
occurrence of PD-related complications. One important source
of this variation might be sex differences in the presentation
of PD (2). For example, numerous studies confirm that the
incidence, and prevalence of PD is higher in men (2–6), that the
disease starts at an earlier age in men (2, 7) and that the disease
progresses faster in men (7, 8). In women, PD tends to be more
often tremor-dominant (2, 7, 9), while in men it is more often the
akinetic-rigid type (2, 10, 11).
We do not know if these sex differences translate to different
patient journeys between men and women with PD. But when
striving for optimal patient-centered and integrated care, it is
vital to understand what the patient journeys look like. As shown
for other diseases (12–15) such insights can be used to improve
access and optimize coordination of care. In this paper, we use
medical claims data to reconstruct the sex-specific journey for
Dutch PD patients during the first 5 years after diagnosis.
In the Netherlands, the patient’s journey starts when a
general practitioner makes a referral to a neurologist when
symptoms of Parkinson’s appear. Neurologists, all located in
hospitals, make the diagnosis. Thereafter, a PD patient visits
the hospital every 3 months, to see their neurologist, who
is supported by nurses or nurse specialists. The nurse and
neurologist work in close collaboration with allied healthcare
professionals in the community, including, e.g., physiotherapists,
occupational therapists and speech and language therapists.
Hospital care is covered by the compulsory health insurance,
whereas allied healthcare services are covered by additional
insurance package, which is not compulsory but taken up by over
80% of the Dutch people. In addition, the Netherlands stands
out with comparatively low out-of-pocket payments (16). This
probably reduces any possible selection bias due to differences
in price responsiveness among PD patients. In the analysis,
we therefore focus on the most frequently involved healthcare
disciplines (neurologists, allied healthcare therapists, and general
practitioners) and on recognized clinical milestones (PD-related
complications, nursing home admission, and death).
MATERIALS AND METHODS
To reconstruct the PD patient journey, we used medical claims
data of all PD patients diagnosed between 2012 and 2016 in
the Netherlands. The dataset was made available through Vektis,
a not-for-profit organization that combines claims data of all
Dutch healthcare insurance companies (17). Since all Dutch
citizens are obliged by law to have a healthcare insurance, the
Vektis database contains the claims data of∼99.8% of the Dutch
population (18) [17.3 million people (19)]. The claims database
contains data on primary care, emergency care and hospital care,
plus nursing home residency. The dataset was anonymized by
Vektis, making available only the sex, year of birth, and a unique
random identifier for each individual. The key to the identifiers
was not available to the researchers.
Similar to a recent paper using similar Dutch claims data
in PD (20), we included only patients who had at least one
diagnosis-related group code (DRG code) for PD. In the
Netherlands, PD can only be diagnosed by a neurologist. We
therefore regarded the first PD-related neurology DRG as the
moment of diagnosis and, as such, as the starting point of
the journey.
To reconstruct the patient journey, we included the
professionals most frequently involved in the treatment of PD.
These are neurologists (together with specialized PD nurses, since
both claim their activities under the DRG code of the hospital),
physiotherapists, occupational therapists, speech and language
therapists, and general practitioners. For every included claim, we
calculated howmany days after the first diagnosis the activity had
occurred. Next, we selected the 1st, 10, 20, and 30th visit to the
general practitioner and the allied healthcare therapists. Unlike
these disciplines, claims related to hospital care are defined in a
DRG model, rather than by a pay-per-visit model. The first PD-
related DRG includes at least one visit to a neurologist, but the
actual number of visits may be higher. A subsequent PD-DRG
can only start 90 days after the initial PD-DRG, and contains at
least one visit to a neurologist or specialized PD nurse. Third and
subsequent PD-DRGs can only start 365 days after the previous
one. Consequently, the maximum number of PD-DRGs within
the first 5 years after diagnosis is six. We therefore selected the
first six PD-DRGs to assess utilization of neurologist. In a similar
way, we identified the time after diagnosis until five clinical
milestones in the patient’s journey had been reached, using a
methodology previously used in a comparable analysis: (21)
nursing home admission, hospitalization for three PD-related
complications (unexpected hospitalization for PD, pneumonia,
orthopedic injuries) (20, 22) and, finally, death.
We used event history analysis with Kaplan-Meyer estimators
to determine after how many days the average patient received
specific care or reached a clinical milestone. This method deals
with differences in length of follow-up between patients. The
follow-up length was calculated for every patient as the number
of days from diagnosis till death or till December 31st 2016, i.e.,
the last data point in the dataset. The median values of the time-
to-event analysis were plotted on a timeline, representing the
journey of the average PD patient. We constructed one timeline
for men, and one for women.We chose median values over mean
values because of the considerable differences in length of follow-
up in our sample. Sex differences were statistically analyzed using
log rank tests.
Standard Protocol Approvals,
Registrations, and Patient Consents
This study was approved by the institutional review board of the
Radboud University Medical Center with a waiver of consent for
participants in the study.
Data Availability Policy
All data, published or not published within the article, is
accessible through Vektis. Analyses were performed in SAS.
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TABLE 1 | General characteristics of the population (n = 22,293).
Men
(n = 13,518; 60.6%)
Women
(n = 8,775; 39.4%)
Age at diagnosis (mean, in years) 71.6 (SD: 9.9) 72.5 (SD: 10.2)
Early onset PD [<50 years at
diagnosis, n (%)]
421 (3.1%) 278 (3.2%)
Length of follow-up (mean) 2.5 years (SD: 1.4) 2.5 years (SD: 1.4)
Living in a nursing home at time of
diagnosis [n (%)]
673 (5.0%) 729 (8.3%)
Death during follow-up [n (%)] 2,469 (18.3%) 1,284 (14.6%)
RESULTS
We included medical claims data of all 22,293 newly diagnosed
patients in the analyses. As shown in Table 1, the population
consists mainly of elderly individuals, a minority of whom lives
in a nursing home before diagnosis.
Healthcare Utilization
Figure 1 shows two timelines representing the sex-specific
patient journey of men and women with PD. Table 2 shows the
inter quartile ranges (IQRs).
Approximately 1 month after diagnosis, patients first visited
their general practitioner (women after 31 days; men after 41).
Thereafter, women saw their general practitioner approximately
once every 6 weeks (43 days). Men saw their general practitioner
less often: approximately once every 8 to 9 weeks (59 days). For
both sexes the frequency declined after the 20th visit (median >5
years for 30th visit). In all analyses, women visited their general
practitioner significantly earlier than men (p-values < 0.001).
Three months after diagnosis, many patients saw their
neurologist or specialized PD nurse again (both for men and
women median = 90 days). However, a substantial part of the
population also visited their neurologist or specialized PD nurse
much later for the second time, i.e., not before 8 to 9 months
after diagnosis [75th quartile value = 210 days (men) and 240
days (women)]. After the second visit, the frequency of claimed
neurology DRGs was about once a year for both sexes, i.e.,
they visited a neurologist or specialized PD nurse at least once
a year. Except for the third visit, where men used neurologist
services slightly earlier than women, no significant sex differences
were found.
Women with PD started their physiotherapy treatment ∼5
months after diagnosis (median = 140 days). Their first 20
physiotherapy sessions took place about once every 5 to 6 weeks.
Men started to visit a physiotherapist later after the diagnosis
then women: 8 months after diagnosis (median= 229 days), and
with a lower frequency: once every seven to 8 weeks. For both
sexes the frequency declined after the 20th session (median >5
years for 30th physiotherapy sessions). In all analyses, women
used physiotherapist services significantly earlier and within a
shorter timespan than men (p-values < 0.001).
For occupational therapists and speech and language
therapists, the median values for the first visits were not reached
within the follow-up time of 5 years. Therefore, they are not
displayed in Figure 1. After 5 years, 37.9% of the women (n
= 3,326) and 33.1% of the men (n = 4,474) had visited an
occupational therapist at least once. This was 18.5% for women
(n = 1,623) and 23.7% for men (n = 3,204) for the first visit to
speech and language therapist. These differences were statistically
significant (p-values < 0.001).
Clinical Milestones
Approximately 2 years after diagnosis, the first PD-related
complication occurred. For women the median value was 1.8
years (IQR = 0.5–>5 years); for men this was 2.3 years (IQR
= 0.6–>5 years; p-value < 0.001). We added the Kaplan-
Meyer curve of this analysis in Figure 2. As shown in Table 2,
orthopedic injuries were the most common complication, and
occurred earlier in the course of the disease in women (p-value
< 0.001). Five years after diagnosis, the percentage of patients
that had experienced at least one PD-related complication was
72.9% in women (n = 6,397) and 68.7% in men (n = 9,287). The
percentage of women admitted to a nursing home rose from 8.3%
(n = 728) before diagnosis to 27.5% (n = 2,413) after 5 years
of PD. In men this increase is from 5.0% (n = 676) to 22.5%
(n = 3,042; p < 0.001). During the first 5 years after diagnosis,
significantly fewer women died (14.6%) than men (18.3%,
p-value=< 0.001).
DISCUSSION
The reconstruction of the Parkinson patient’s journey through
the Dutch healthcare sector during the first 5 years after
diagnosis, reveals quantitative information about healthcare
utilization and the occurrence of clinical milestones over time. It
also reveals sex differences: in the Netherlands, women visit most
of the included healthcare professionals sooner after diagnosis
and more frequently. In addition, PD-related complications
occur earlier in women than in men. A sizeable subgroup of
patients is admitted to nursing homes within 5 years after
diagnosis. Again, this happens more frequently in women.
Finally, 14.6% of the women and 18.3% of the men died within
5 years after the diagnosis.
Relation With Previous Findings
Our findings confirm and extend earlier work, from both
inside and outside the Netherlands. The characteristics of our
population are comparable to earlier work when it comes to
general incidence (23) and the male predomination of the disease
(2–6). Comparable values for age at diagnosis and percentage
of early-onset PD were also found before (24). However, while
most studies found a faster disease progression in men (7,
8), our findings suggest a more rapid disease progression in
women, since they visited their healthcare professionals sooner
and experienced orthopedic injuries earlier and more often after
diagnosis. However, there might be other explanations for this
observation. First, the included women were living relatively
more often in a nursing home before diagnosis, indicating that
they were probably in a worse physical condition at the outset.
This might make them more prone to develop complications
and also explain the more intense healthcare utilization. Patients
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TABLE 2 | Time (in days, since diagnosis) till relevant provider contacts and clinical milestones during the patient journey, by sex.
Women median (1st−3rd
quartile)
Men median (1st−3rd
quartile)
P-value
PROVIDER CONTACT
1st neurology DRG 0 (0–0) 0 (0–0) 0.270
2nd neurology DRG 90 (90–240) 90 (90–210) 0.079
3rd neurology DRG 455 (360–>1,826) 455 (330–1,454) 0.040
4th neurology DRG 820 (575–>1,826) 820 (575–>1,826) 0.280
5th neurology DRG 1,185 (935–>1,826) 1,185 (935–>1,826) 0.348
6th neurology DRG 1,545 (1,180–>1,826) 1,430 (1,180–>1,826) 0.333
1st general practitioner visit 31 (8–87) 41 (11–116) <0.001
10th general practitioner visit 428 (231–824) 574 (301–1,112) <0.001
20th general practitioner visit 863 (505–1,605) 1,178 (659–>1,826) <0.001
30th general practitioner visit >1,826 (830–>1,826) >1,826 (1,082–>1,826) <0.001
1st physiotherapist visit 140 (16–826) 229 (38–1,303) <0.001
10th physiotherapist visit 460 (136–>1,826) 679 (177–>1,826) <0.001
20th physiotherapist visit 877 (268–>1,826) 1,202 (341–>1,826) <0.001
30th physiotherapist visit >1,826 (415–>1,826) >1,826 (530–>1,826) <0.001
1st occupational therapist visit >1,826 (986–>1,826) >1,826 (1247–>1,826) <0.001
1st speech and language therapist visit >1,826 (>1,826–>1,826) >1,826 (>1,826–>1,826) <0.001
CLINICAL MILESTONES
Nursing home admission >1,826 (1,571–>1,826) >1,826 (>1,826–>1,826) <0.001
1ST PD-RELATED COMPLICATION
Pneumonia >1,826 (661–>1,826) >1,826 (686–>1,826) 0.879
Orthopedic injuries 1114 (347–>1,826) >1,826 (527–>1,826) <0.001
Hospitalization >1826 (>1,826–>1,826) >1,826 (>1,826–>1,826) 0.359
All PD-related complications 646 (179–>1,826) 828 (214–>1,826) <0.001
Death >1,826 (>1,826–>1,826) >1,826 (>1,826–>1,826) <0.001
living in nursing homes might also have easier access to
the in-house allied health therapists. Second, the findings can
indicate a doctor or patient delay in the diagnostic process in
women, meaning that women receive the diagnosis relatively
late in the course of the disease. This has been found earlier
(25). Alternatively, women might find their way to healthcare
professionals more effectively (or faster). This has been observed
for other diseases (26, 27) but not previously for PD.
What surprised us was the high mortality rate and that
patients experienced their first PD-related complication already
2 years after the diagnosis. No PD-specific literature is available
to compare these results with. The average age at onset of 72 years
is in line with other population-based cohort studies (28–30). The
finding that 5.08.3% of the patients are living in a nursing home
at diagnosis, which are relatively high, can be understood when
considering that the Netherlands has relatively one of the largest
long term care sectors in the world (31). Given that patients living
in a nursing home are likely more vulnerable, this might explain
the mortality and complication rates.
Strengths and Limitations
Our methods have strengths and limitations. An important
strength is that our dataset contained all newly diagnosed patients
in the country over a period of 5 consecutive years. This reduces
a potential selection bias. However, some selection may have
resulted from our inclusion criteria. Since we included all patients
with a first PD DRG, there might be some cases where the initial
diagnosis of PD was wrong. PD is hard to diagnose, with reported
diagnostic error rates of >10% (32). Therefore, we cannot
exclude that some patients had other conditions, in particular
one of the forms of atypical parkinsonism (23). Our sample
most likely included people who were incorrectly diagnosed. A
review of the literature, including 11 studies, concluded that
the validity of clinical diagnosis of PD is not satisfying, which
was the case for both non-experts and movement disorder
specialists (33). We were not able to correct for this error
in our analysis. However, since our population characteristics
matched well with previous reports, we do not think that all
these factors affected our data on a large scale. Moreover, it
is unlikely that this diagnostic error affected men and women
differentially. Another strength is that our study is based on
highly standardized claims data. And we only used items that,
although self-reported by healthcare professionals, are known to
be reliably completed (34).
As claims data don’t include detailed information about
the clinical status of the patients, we were not able to correct
for factors that confound and/or modify the relationship
between sex and complications (35). This holds particularly
true for co-morbidity and PD-related complications that are
more frequently associated to female sex (e.g., dyskinesia,
motor, and non-motor complications) (11). Also, the sex-
difference in the occurrence of orthopedic injuries might
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FIGURE 1 | Timeline of the average Parkinson’s patient journey during the first 5 years after diagnosis. DRG, diagnosis related group; GP, general practitioner; PD,
Parkinson’s disease.
FIGURE 2 | Kaplan-Meyer curve of the time-to-event analysis for PD-related
complications.
be explained by the female predominance in osteoporosis.
Therefore, our findings require confirmation in other,
independent datasets.
Finally, our findings might be difficult to extrapolate to other
countries with another organization of the healthcare system.
For example, duration of visits and treatment intensity can differ
between countries. Moreover, the presence of ParkinsonNet in
the Netherlands contributed to the quality and role of allied
health care professionals, and stimulated access to specialized and
multidisciplinary Parkinson care (36).
Practical Implications
Comparable work on other diseases suggests that our
reconstruction of the patient journey may lead to better
patient-centered care delivery. Specifically, it provides healthcare
professionals an overview of where and when particular
physicians get involved, which might reveal errors in providers’
perspectives (37). It might act as a useful tool to gain insight
in patient experiences (12, 37), to reveal barriers to access
(13, 38), to detect gaps in care delivery (39, 40), and to improve
coordination and quality of care (38, 41). The identified sex
differences might contribute to the debate about differences
in PD between men and women, extending earlier work on
different phenotypes to now include contrasts in healthcare
utilization as well. We hope these insights can lead to better and
more personalized care for PD patients of both sexes.
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